Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542175 · ClinicalTrials.gov registry record · Phase 1
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT03542175: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03542175 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03542175, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast cancer.
Interventions
- RADIATION Radiotherapy
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-05-23 |
| Est. Completion | 2025-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03542175
The ClinicalTrials.gov registry entry for NCT03542175 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiotherapy is the first listed.
NCT03542175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03542175 about?
NCT03542175 is a clinical study titled "A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy". The purpose of this study is to test the safety of a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast cancer.
What is the current status of trial NCT03542175?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2018-05-23. Estimated completion is 2025-09-10.
What interventions are being tested in trial NCT03542175?
The interventions under investigation include: Radiotherapy (RADIATION), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03542175?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.